Articles from Beeline Medicines Corporation

– Study met its primary endpoint, with afimetoran demonstrating higher SRI-4 response rates versus placebo at Week 48 (p-value <0.001 across all dose groups) –

– $126.3 million of new funding adds to previously announced $300 million Series A financing – 

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –